SubjectWell Welcomes Karl Stubelis as New CFO to Enhance Financial Strategies and Growth

SubjectWell Appoints Karl Stubelis as Chief Financial Officer

SubjectWell, a prominent Patient Experience Platform focused on enhancing clinical trial enrollment and patient retention, recently announced the appointment of Karl Stubelis as their Chief Financial Officer (CFO). With over 25 years of extensive leadership experience in high-growth healthcare, life sciences, and technology sectors, Stubelis is poised to steer the company's financial strategy as it continues to scale its offerings and broaden its international presence.

Karl Stubelis brings with him an impressive track record of success, having worked with venture-backed startups, private equity firms, and publicly traded companies. His most recent position was CFO at Verb Biotics, where he was instrumental in crafting the financial strategy within the emerging probiotics landscape. Furthermore, Stubelis previously held senior roles at Exact Sciences and Thrive Earlier Detection, contributing significantly to Thrive's remarkable multi-billion-dollar acquisition by Exact Sciences.

Stubelis's credentials also include vital leadership positions in several Software as a Service (SaaS) health companies such as Athenahealth, Ovia Health, and Arcadia. During his tenure at Athenahealth, he oversaw global financial operations while successfully navigating the intricate dynamics of public markets, dealing with activist investors, and adapting to regulatory changes.

Early in his career, Stubelis's global influence expanded as he held international finance leadership roles at Sapient, where he managed finance teams across over 15 countries. His vast experience and multifaceted expertise are expected to play a pivotal role at SubjectWell, particularly as the company embarks on a new era of growth.

Fred Martin, CEO of SubjectWell, expressed enthusiasm about Stubelis's appointment: "As SubjectWell enters a new chapter of growth, Karl's experience at the intersection of healthcare and technology positions him to play a critical role in our continued evolution. His proven track record in scaling operations, executing strategic transactions, and guiding companies through pivotal transitions will be instrumental as we broaden our global reach and deepen our impact on the clinical trial ecosystem—benefitting patients, customers, and communities worldwide."

Karl Stubelis holds a Bachelor of Science in Finance from the University of Vermont and earned his MBA from Suffolk University. His academic background, combined with rich industry experience, sets the stage for a transformative impact at SubjectWell.

About SubjectWell

SubjectWell is at the forefront of transforming the clinical trial landscape through its platform that enhances patient experience. The company strategically drives predictable clinical trial enrollment and significantly improves retention rates by refining the patient journey from protocol design to the completion of studies. With an emphasis on technology, a global reach, and full-service creative solutions, SubjectWell mitigates burden for sites and strengthens operational efficiency for sponsors, Clinical Research Organizations (CROs), and site networks. From protocol development through recruitment, enrollment, and retention, to post-trial real-world evidence studies, SubjectWell supports the entire clinical trial lifecycle, enhancing the experience for everyone involved.

For more information, you can contact Alysha Swisher or Haylee Elmore at Interdependence Public Relations at 602-350-1455 or via email at [email protected].

As SubjectWell moves forward under the financial leadership of Karl Stubelis, the company is set to leverage its innovative technology to make significant strides in the clinical trial arena, ensuring a better experience for both patients and researchers alike.